GV1001

The literature is large and the randomised human evidence is almost entirely negative, which is an unusual combination and the central thing to understand.

The pivotal trial is TeloVac, funded by Cancer Research UK and run across 51 UK hospitals ^[1]. It randomised 1,062 patients with advanced pancreatic cancer to chemotherapy alone, chemotherapy with sequential GV1001, or chemotherapy with concurrent GV1001. Median overall survival was 7.9 months for chemotherapy alone, 6.9 months with sequential vaccine and 8.4 months with concurrent vaccine; the hazard ratios were 1.19 and 1.05, both above one, and the overall test was not significant. The authors concluded that adding GV1001 did not improve survival.

A later Korean phase 3 in eotaxin-high pancreatic cancer reported longer survival, 11.3 against 7.5 months ^[6], but it was open-label, the arms were not biomarker-matched, dropout differed sharply between them, the censoring was severe enough that the usual survival analysis had to be abandoned for an alternative estimator, no hazard ratio was reported, and the eotaxin hypothesis failed its own multivariate test.

Other programmes ended quietly. A phase 3 in a second pancreatic setting was terminated, a phase 3 in lung cancer was never reported, and a phase 2 in liver cancer found no complete or partial responses and no detectable GV1001-specific immune responses at all ^[7].

Current work is in benign prostatic hyperplasia, where a phase 3 against finasteride ran with no placebo arm and the drug did not significantly reduce prostate volume, and in Alzheimer's disease, where one 96-patient phase 2 has been published, a 199-patient phase 2 completed in 2025 remains unpublished, and the phase 3 has not begun.

The safety record is the strongest thing about this compound. Across roughly twenty years and more than 1,500 exposed patients in oncology trials, adverse effects have been predominantly injection-site reactions, and no pattern of serious toxicity has emerged ^[1].

One negative deserves highlighting because it was a genuine a priori concern: telomerase is expressed in blood-forming progenitor cells, so a vaccine directed at telomerase-expressing cells carried a theoretical risk of bone-marrow damage. No bone-marrow toxicity appeared in long-term immune responders.

⚠️ No pharmacokinetic data has ever been published. There is no reported peak concentration, half-life or clearance for GV1001 in humans. The first dedicated healthy-volunteer pharmacokinetic study completed in August 2025, roughly twenty years after the first oncology trials, and has posted no results.

It holds a conditional Korean approval for advanced pancreatic cancer, granted in 2014 before its confirmatory trial reported. It is not approved by the FDA or EMA for anything.

GV1001 was developed in Norway and Korea in the late 1990s on a then-compelling premise: telomerase is switched on in the great majority of cancers and largely off in normal adult tissue, so a vaccine against a telomerase peptide should be broadly applicable and comparatively safe. It was designed as a promiscuous class II binder so that it would work across most of the population rather than a single tissue type. The safety half of that prediction held up completely. The efficacy half did not survive TeloVac, the large independently funded trial that reported in 2014 and found no survival benefit. The programme afterwards moved away from oncology entirely, into prostate enlargement on the strength of a gonadotropin-releasing hormone receptor mechanism, and into neurodegeneration. Along the way the compound acquired a second life in the supplement and peptide-vendor market as an anti-aging telomerase product, a use that has no relationship to what the molecule was built to do.